Omeros Corporation Secures $22 Million in Registered Direct Offering Through D. Boral Capital LLC

Omeros Corporation (NASDAQ: OMER) recently completed a registered direct offering that raised approximately $22 million, with D. Boral Capital LLC acting as the exclusive placement agent. The transaction, which closed on July 28, 2025, involved the sale of 5,365,853 shares of common stock at $4.10 per share. This price represented a 14% premium to the closing price on July 24, 2025, the date of the securities purchase agreement. The offering was conducted under a 'shelf' Registration Statement on Form S-3 (File No. 333-268269) and the accompanying prospectus, highlighting the strategic financial approach Omeros Corporation is employing to strengthen its position within the biopharmaceutical industry.

The involvement of Polar Asset Management Partners as a key investor in this transaction underscores the confidence in Omeros's potential and the strategic importance of this capital infusion. This successful offering provides Omeros Corporation with necessary funds to advance its research and development initiatives, which is crucial for navigating the challenges of drug development and commercialization in a highly competitive market. The transaction also highlights the growing investor interest in the biopharmaceutical sector, where companies require substantial capital to bring innovative therapies from research laboratories to patients.

D. Boral Capital LLC's expertise in navigating complex financial landscapes is evident in this transaction, further cementing its reputation as a premier investment bank for middle-market and emerging growth companies. With a track record of aggregating approximately $30 billion in capital since its inception in 2020, the firm continues to demonstrate its ability to deliver tailored financial solutions across diverse sectors worldwide. For more information on D. Boral Capital LLC, visit https://dboralcapital.com/.

The transaction serves as a testament to the robust financial strategies employed by companies like Omeros to secure funding during critical development phases. In the biopharmaceutical industry, where research timelines are lengthy and regulatory hurdles are significant, access to capital can determine whether promising therapies reach the market. This offering not only strengthens Omeros's financial position but also signals to the broader market that well-structured financial transactions can attract premium pricing even in challenging economic environments. The 14% premium achieved in this offering demonstrates that investors are willing to pay above market rates for strategic opportunities in the life sciences sector.

The successful closure of this offering represents more than just a financial transaction; it reflects the ongoing evolution of capital formation strategies in the biopharmaceutical industry. As companies seek alternatives to traditional public offerings, registered direct offerings have emerged as an efficient method to raise capital while minimizing market disruption. This approach allows companies to work with sophisticated institutional investors who understand the long-term value proposition of biopharmaceutical research. The transaction's structure, executed under an existing shelf registration, enabled Omeros to move quickly to secure funding, demonstrating the importance of having flexible financial instruments available when market conditions are favorable.